Schaack Alice K, Allamong Maxwell B, Hung Frances, Barfield Richard T, Wilson Sarah M, Watkins Tina, Link Katherine, McKellar Mehri S
Duke School of Medicine, Duke University, Durham, NC, USA.
Social Science Research Institute, Duke University, Durham, NC, USA.
AIDS Behav. 2025 Jun 17. doi: 10.1007/s10461-025-04749-0.
Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has potential to increase PrEP uptake and adherence. However, most studies investigating opinions about LAI PrEP were done prior to its approval. We administered a cross-sectional electronic survey to clients at an urban PrEP clinic in the U.S. South. Eligible participants were 18 + and had previously taken or been prescribed oral or LAI PrEP. They were asked their opinions on PrEP, barriers to access, perceived HIV risk, and PrEP stigma. Between January and April 2024, 123 people participated. Twenty-two (17.9%) used LAI PrEP, 80 (65.0%) oral PrEP, and 21 (17.1%) were not currently using PrEP. Most participants identified as men (87.8%), and mean age was 38.6 (range 19-78). Participants were 52.8% White, 27.6% Black, and 14.6% Latinx. 56.1% preferred injection versus daily oral pill. Common concerns about PrEP included side effects (n = 48), cost of medication (n = 21), and cost of clinic visits/tests (n = 21). Of those taking oral PrEP, 56.3% reported remaining on oral because LAI was not offered to them and/or they were not aware of it. Perceived HIV risk scores were on average higher for those not currently taking PrEP (not on = 26.8, SD = 6.54; LAI = 22.3, SD = 6.45; oral = 24.2, SD = 6.13). Overall, participants had low to moderate PrEP stigma scores. Despite majority preference for LAI PrEP, patients are frequently unaware of or not offered LAI. Common concerns about PrEP include side effects and costs. These data demonstrate the importance of improving LAI PrEP awareness and accessibility of choice.
长效注射用暴露前预防（PrEP）有潜力提高PrEP的接受率和依从性。然而，大多数关于长效注射用PrEP看法的研究是在其获批之前进行的。我们对美国南部一家城市PrEP诊所的客户进行了一项横断面电子调查。符合条件的参与者年龄在18岁及以上，之前曾服用过或被开了口服或长效注射用PrEP。他们被问及对PrEP的看法、获取障碍、感知到的艾滋病毒风险以及PrEP污名化情况。在2024年1月至4月期间，有123人参与。22人（17.9%）使用长效注射用PrEP，80人（65.0%）使用口服PrEP，21人（17.1%）目前未使用PrEP。大多数参与者为男性（87.8%），平均年龄为38.6岁（范围19 - 78岁）。参与者中52.8%为白人，27.6%为黑人，14.6%为拉丁裔。56.1%的人更喜欢注射方式而非每日口服药片。对PrEP的常见担忧包括副作用（n = 48）、药物成本（n = 21）以及诊所就诊/检查费用（n = 21）。在服用口服PrEP的人中，56.3%报告称继续服用口服PrEP是因为未向他们提供长效注射用PrEP和/或他们不知道有这种药。目前未服用PrEP的人感知到的艾滋病毒风险评分平均更高（未服用 = 26.8，标准差 = 6.54；长效注射用 = 22.3，标准差 = 6.45；口服 = 24.2，标准差 = 6.13）。总体而言，参与者的PrEP污名化评分较低至中等。尽管大多数人更喜欢长效注射用PrEP，但患者经常不知道有这种药或未被提供。对PrEP的常见担忧包括副作用和成本。这些数据表明提高长效注射用PrEP的知晓度和选择的可及性很重要。
